Document ID: chunk:federal_register_of_legislation:F2024C01086:clause:1_18375
Version: federal_register_of_legislation:F2024C01086
Segment Type: clause
Provision Reference: sch 1 cl 18375
Character Range: 1038851–1040383

18375                      Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), intravesial injection of, with cystoscopy, for the treatment of urinary incontinence, including all such injections on any one day, if:                                                                                                                                                                                            239.20
                           (a) the urinary incontinence is due to neurogenic detrusor overactivity as demonstrated by urodynamic study of a patient with:
                           (i) multiple sclerosis; or
                           (ii) spinal cord injury; or
                           (iii) for a patient who is at least 18 years of age—spina bifida; and
                           (b) the patient has urinary incontinence that is inadequately controlled by anti‑cholinergic therapy, as manifested by having experienced at least 14 episodes of urinary incontinence per week before commencement of treatment; and
                           (c) the patient is willing and able to self‑catheterise; and
                           (d) the treatment is not provided on the same occasion as a service described in item 104, 105, 110, 116, 119, 11900 or 11919
                           Applicable only once unless the patient achieves at least a 50% reduction in urinary incontinence episodes from baseline at any time during the period of 6 to 12 weeks after first treatment
                           (H) (Anaes.)